Margaret Foley, OD
Optometrist · Eugene, ORNPI 1194774224
Payments from drug & device makers
What this record shows
This record is dominated by speaking fees: $52,734 of the $66,999 with a category attached, or 78.7%. 15 manufacturers reported payments, led by Bausch & Lomb Americas Inc. at 36.8% of the total. 2025 is the largest year on record at $23,426, 2.1 times the $11,371 reported in 2019. Among optometrist clinicians in OR with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 204 payments — averaging $328.43 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Bausch & Lomb Americas Inc.$25K
- AbbVie$19K
- Tarsus Pharmaceuticals, Inc.$10K
- Shire North American Group Inc$9K
- Alcon$2K
- Novartis$1K
- plus $1K from 9 others
What the payments were for
- Consulting fees$9981%
- Speaking & faculty fees$52,73479%
- Travel & lodging$9,00213%
- Food & beverage$4,1986%
- Education$300%
- Gifts$390%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Bausch & Lomb Americas Inc. | 60 | $24,624 |
| AbbVie(2 entities) | 35 | $18,904 |
| Tarsus Pharmaceuticals, Inc. | 39 | $10,306 |
| Shire North American Group Inc | 10 | $8,734 |
| Alcon | 16 | $2,286 |
| Novartis | 5 | $1,076 |
| Sun Pharmaceutical Industries Inc. | 26 | $537 |
| Galderma Laboratories, L.p. | 2 | $175 |
| Oyster Point Pharma, Inc. | 2 | $123 |
| Heidelberg Engineering, Inc. | 1 | $94 |
| Bausch & Lomb, A Division Of Bausch Health US, LLC | 3 | $44 |
| Carl Zeiss Meditec AG | 2 | $39 |
| Thea Pharma Inc. | 1 | $21 |
| Biotissue Holdings Inc. | 1 | $18 |
| Sight Sciences, Inc. | 1 | $18 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- XIIDRA$31,141
- MIEBO$22,955
- XDEMVY$9,770
- VUITY$8,994
- RESTASIS$4,898
- RESTASIS MULTIDOSE$4,788
- DAILIES$1,500
- DAILIES TOTAL1$500
- Precision 1$500
- BLINK NUTRITEARS$500
- CEQUA$216
- TYRVAYA$101
How this compares
$66,999 in reported general payments places this provider in the 95th percentile of 684 optometrist providers in Oregon.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| XdemvyLotilaner | 107 | $202,352 |
| MieboPerfluorohexyloctane/Pf | 74 | $58,681 |
| TyrvayaVarenicline Tartrate | 47 | $53,525 |
| RestasisCyclosporine | 30 | $30,982 |
| Cyclosporine | 24 | $10,661 |
| Latanoprost | 28 | $267 |
| Azithromycin | 30 | $139 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Tarsus Pharmaceuticals, Inc.Xdemvy | $10,306 | $202,352107 claims |
| Bausch & Lomb Americas Inc.Miebo | $24,624 | $58,68174 claims |
| Oyster Point Pharma, Inc.Tyrvaya | $123 | $53,52547 claims |
| AbbVieRestasis | $18,904 | $30,98230 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 684 optometrist providers in Oregon.
Other optometrist in Eugene
- Alexandria JernbergEugene$6K
- Dominic LemasEugene$5K
- Amber DunnKing City$284K
- Roger TabbPortland$239K
- Mila IoussifovaPortland$223K
- Cristina SchniderForest Grove$204K
- Tracy DollPortland$164K
- Yue LiuForest Grove$139K
- Shajida Espat ReichMedford$87K
- Bradley SmithTigard$85K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.